How to gain a competitive advantage in a fast-changing pharmaceutical supply ecosystem.
The global Covid-19 pandemic as well as geopolitical tensions and trade restrictions have drawn attention to profound geographical, technical, and structural shifts in pharmaceutical supply chains. Treatments are increasingly produced by highly capable contract development and manufacturing organizations (CDMOs). As new, extraordinarily sophisticated, advanced therapies (ATx) emerge to complement traditional large and small molecule treatments, this trend looks set to deepen and accelerate. Today, CDMOs are targeting an increasingly attractive business segment, in which pure play CDMOs and other market participants are taking on a growing role.
Continue reading Strategy&’s 2022 Global CDMO Study of Pharmaceutical Operations
1) General background information
As a consequence of the failed MRA between CH and the EU, EU certificates (i.e., medicinal products with SQS certificate) which were issued by the respective Swiss body, shall no longer be recognized in the EU and an EU representative is required.
Continue reading Update: Mutual Recognition Agreement CH-EU
Swiss Medtech companies have recently engaged national associations in order to take action against the so-called SQS ban by the EU Commission.
24 November 2021 or 25 November 2021
Dear Pharma and Life Science Colleagues,
Thank you for your interest in our virtual round table on ESG, regulation and rebates in the health industry. This event will be held online on Wednesday 24 November 2021 from 15:00 to 16:00 CET, and again on Thursday 25 November 2021 from 09:00 to 10:00 CET.
Using environmental, social and governance (ESG) metrics to evaluate companies and countries on their progress towards sustainability has become a hot topic all around the world. Alongside these issues, the health sector is also facing major regulatory challenges.
Continue reading Indirect Tax virtual round table
Die Mehrwertsteuer, insbesondere im Pharma Bereich für Konzerne, KMUs und Start-ups, ist im steten Wandel und immer transparenter.
Für Sie als Entscheidungsträger im Pharma & Life Sciences Bereich, wird es immer schwieriger all die gesetzlichen und behördlichen Vorgaben / Neuerungen effizient und kostengünstig einzuhalten. Dazu kommt die anhaltende COVID-19-Situation, welche umsatzsteuerliche Herausforderungen mit sich bringt und die es zu meistern gilt. Gleichzeitig spielt Industrie 4.0 und die umfassende Digitalisierung in der industriellen Produktion eine immer wichtigere Rolle. Dieser absehbare Wandel bringt neue Chancen zur Prozessoptimierung.
Continue reading PwC’s 6. Schweizer MWST-Tagung
ESG stands for ‘environmental, social and governance’ – without a doubt a global mega trend, and even more so in the post Covid-19 world.
During this webinar, we will look at how a strong ESG proposition can create value. In particular, we will illustrate the value creation process by providing a framework tailored to the pharma value chain to describe the various options.
Continue reading Webinar: How can ESG create value in the pharma industry?
Switzerland and the EU did not reach a consensus on the negotiations of the Institutional Framework Agreement. As a consequence, the Mutual Recognition Agreement (MRA) between the EU and Switzerland and related provisions for medical devices were not updated and, therefore, ceased to apply on 26 May 2021. With that, as of now Switzerland is considered as a ‘third country’ and Swiss MedTech companies lost their previously barrier-free access to the EU market and vice versa. The following article shows what companies selling medical devices need to consider when exporting to the EU or Switzerland.
Continue reading Trade obstacles for MedTech companies due to the failed negotiations on the EU-Switzerland Institutional Agreement
Dear pharma members
Germany has recently published a court decision with major impact on the pharma supply chain (commercial and clinical) in the EU Member States:
Continue reading WEBINAR – Pharma news: German court decision – Sale of drugs from a Swiss company and new EU requirements
We are delighted to invite you to our virtual Global Indirect Tax Health Industry Convention “Succeeding through uncertainty” on Thursday 6 May 2021 from 2pm to 6pm CEST. We will discuss the latest hot topics in the pharma, healthcare and life science industry from an indirect tax perspective and beyond.
Continue reading Webinar – Global Indirect Tax Health Industry Convention, 6 May 2021 2pm–6pm CEST
The incredible pace of change in indirect taxes in the pharma, healthcare and life sciences industry shows no sign of slowing down. Digital transformation, changes in supply chains due to the pandemic, Brexit and complex developments in EU legislation are just some of the factors that are currently having a major impact on this industry and affecting almost every aspect of our business lives.